Apparently, on the grounds of the public interest in competition in the medical device field, the CAFC refused a permanent injunction against the defendant, a competitor of the patentee/plaintiff. Having found infringement of the patent, the only relief awarded was an ongoing equitable royalty. There was apparently no finding of bad faith on the part of the patentee.
This Kat has nothing at present to add to the analysis by Dave Healey. From his UK perspective, he is quite surprised that the US courts are apparently accepting in principle that a public interest in competition can reduce the remedies available to that of a reasonable royalty.
Yet another 2:1 result at the CAFC. I am increasingly thinking that CAFC judging panels are doing this deliberately, to provoke discussion (and perhaps, as Healy surmises, en banc review).
ReplyDeleteFor more than 30 years now, The EPO has done it more elegantly. Different Boards of Appeal pursue different lines of legal logic till the issue is ripe, and then the Enlarged Board announces, (basta!), the settled line that all the TBA should henceforth follow.
I think (not completely tongue in cheek) that Randall Rader CJ is jealous of DG3's 24 TBA,1000+ cases p.a. and its EBA. Has the AC invited him yet, to join the other national specialist patent law judges listed as members of the EBA?